Pantoprazole 40 mg Is as Effective as Esomeprazole 40 mg to Relieve Symptoms of Gastroesophageal Reflux Disease after 4 Weeks of Treatment and Superior regarding the Prevention of Symptomatic Relapse
Authors:
- Muwafeg Abdel-QaderMAMuwafeg Abdel-Qader
- Gudrun GatzGGGudrun Gatz
- Bernd PfaffenbergerBPBernd Pfaffenberger
- 1 May 2007
- journal article
- research article
- Published by S. Karger AG in Digestion
- Vol. 75 (Suppl. 1) , 69-78
Abstract
Background/Aim: Little is known about the symptom course during and after treatment of gastroesophageal reflux disease (GERD). Here we address this question in patients with erosive GERD treated with pantoprazole or esomeprazole 40 mg once daily using the validated reflux questionnaire ReQuestTM. Methods: Of 585 patients enrolled, 561 (intention-to-treat; ITT) patients with endoscopically confirmed GERD grades A–D (Los Angeles Classification) were randomized. To assess the GERD symptomatology, the patients completed the ReQuest daily, and analysis was done prior to (7 days), during (28 days), and after treatment (7 days). The mean scores (last 3 treatment days) of the subscale ReQuestTM-GI (gastrointestinal complaints) were compared between both groups. After the end of treatment, the number of symptom episodes and the rate of relapses were calculated. Results: Noninferiority of pantoprazole versus esomeprazole during treatment was shown (mean ReQuest-GI score). During the posttreatment period, the proportion of patients experiencing a symptomatic relapse (51 vs. 61%, p = 0.0216, ITT) and the number of symptom episodes (0.56 vs. 0.74, p = 0.0095, ITT) were significantly lower on pantoprazole than on esomeprazole. Conclusions: Pantoprazole 40 mg was at least as effective as esomeprazole 40 mg for relieving GERD symptoms. During the posttreatment phase, patients on pantoprazole had a significantly lower risk to relapse and experienced significantly fewer symptom episodes.Keywords
This publication has 34 references indexed in Scilit:
- Pantoprazole 20???mg on demand is effective in the long-term management of patients with mild gastro-oesophageal reflux diseaseEuropean Journal of Gastroenterology & Hepatology, 2005
- Determination of ReQuest™-Based Symptom Thresholds to Define Symptom Relief in GERD Clinical StudiesDigestion, 2005
- Novel Measurement of Rapid Treatment Success with ReQuestTM: First and Sustained Symptom Relief as Outcome Parameters in Patients with Endoscopy-Negative GERD Receiving 20 mg Pantoprazole or 20 mg EsomeprazoleDigestion, 2005
- Heartburn in primary care: problems below the surfaceJournal of Gastroenterology, 2004
- International validation of ReQuest in patients with endoscopy-negative gastro-oesophageal reflux diseaseAlimentary Pharmacology & Therapeutics, 2004
- Management strategies for gastroesophageal reflux diseaseJournal of Gastroenterology and Hepatology, 2004
- Evaluation of GERD Symptoms during Therapy. Part IIDigestion, 2004
- Process of Measuring in Clinical Medicine – Implications of Different Definitions in Clinical Therapeutic StudiesDigestion, 2004
- Maintenance therapy with pantoprazole 20 mg prevents relapse of reflux oesophagitisAlimentary Pharmacology & Therapeutics, 1999
- Endoscopic assessment of oesophagitis: clinical and functional correlates and further validation of the Los Angeles classificationGut, 1999